MSD’s Keytruda Combines with PharmAbcine’s PMC-309 in Phase Ia/b Solid Tumor Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its blockbuster anti-PD-1 drug Keytruda...
NMPA Proposes Streamlined Market Approval Process for Domestically Produced Overseas Drugs
The National Medical Products Administration (NMPA) has released a draft proposal titled “Optimizing the Market...
GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s...
NMPA Expands Generic Drug Catalog with 74th and 75th Batches for Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 74th and 75th batches of reference...
China Grand Pharmaceutical Gets NMPA Green Light for mRNA Cancer Vaccine ARC01 Phase I Study
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...
China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation...
Boan Biotech Secures FDA Orphan Drug Designations for Two Claudin18.2 Targeting Candidates
Boan Biotech (HKG: 6955), a Chinese biotechnology company, has announced that it has received orphan...
Alphamab and 3D Medicines License Envafolimab Rights to Glenmark for Multiple Regions
Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244), two Chinese pharmaceutical companies, have announced...
Lingyi Biotechnology’s Gene Therapy Candidate LY-M001 Gets FDA Green Light for Gaucher’s Disease
Lingyi Biotechnology Co., Ltd, a China-based gene therapy developer, has secured clinical trial approval from...
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China,...
Phanes Therapeutics’ First-in-Class BsAb PT217 Accepted for Review by China’s CDE
Sino-US biotechnology company Phanes Therapeutics Inc. has announced that the Investigational New Drug (IND) filing...
Zhaoke Ophthalmology Secures NMPA Approval for Presbyopia Treatments Brimochol PF and CarbacholPF
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
Harbour BioMed Gets FDA Green Light for Phase I Study of BsAb Targeting PD-L1 and CD40
Harbour BioMed (HKG: 2142), a biotechnology company with operations in Suzhou, China, Cambridge in the...
Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline
US healthcare company Abbott (NYSE: ABT) has released its financial results for the fourth quarter...
Sanofi Acquires Rare Disease Candidate INBRX-101 in $1.7 Billion Deal
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced the acquisition of INBRX-101, a promising candidate...
Eli Lilly’s Olumiant Patent Invalidated in China, Generic Version Approved
The China National Intellectual Property Administration (CNIPA) has declared the compound patent CN200980116857.7 for Eli...
BMS’s Opdivo-Yervoy Combo Cuts Cancer Progression Risk by 79% in Phase III Study
Bristol Myers Squibb (BMS; NYSE: BMY) has published late-stage and long-term data for its anti-PD-1...
Tcelltech’s B7-H3 Targeting CAR-T Therapy TX103 Gets Tacit Clinical Approval for Glioblastoma
The Center for Drug Evaluation (CDE) website in China has indicated that Tcelltech’s TX103, a...
Merck’s Bavencio Shows Promising Survival Data in Real-World Urothelial Carcinoma Studies
German pharmaceutical company Merck (NYSE: MRK) has released data from real-world studies for its anti-PD-L1...
BriSTAR Immunotech’s LILRB4-Targeted Cell Therapy YTS104 Gets Tacit Approval for Clinical Trial in China
BriSTAR Immunotech, a clinical-stage cell therapy company based in Beijing, has received tacit clinical trial...